S

Sanofi

Global pharma company; vaccines and R&D

Talent Acquisition Partner-Early Careers - Talent Services

Full-TimePosted on 10/23/2026Deadline 11/20/26
No salary listed
Senior
Bachelor's
Hyderabad, Telangana, India
In Person
People & HRGeneralist Recruiting

About the job

Requirements
  • Significant expertise in supporting early talent hiring, with a strong focus on local and global employment market dynamics; experience in Global Business Services organizations is an added advantage.
  • Bachelor's degree and 7–8 years of recruiting experience in campus placements.
  • Project management skills and ability to drive results, with business acumen and an understanding of how early talent strategy impacts the business.
  • Good judgment and ability to interface effectively with employees and leaders at all levels.
  • Effective time management and organizational skills, with the ability to prioritize while managing numerous projects and processes under tight deadlines.
  • Excellent communication and presentation skills.
Responsibilities
  • Manage a large volume of early-career requisitions using online platforms, university job boards, career fairs, social media, and other sourcing channels to identify and engage qualified candidates.
  • Conduct campus engagement events and develop and execute engagement programs with campus stakeholders, including student communities, career services offices, faculty, and alumni, to position Sanofi as an employer of choice.
  • Advise the business on university relations by assessing client needs, explaining the campus landscape, setting expectations based on market intelligence, and partnering to forecast annual campus hiring needs; adapt to on-campus changes and address unforeseen challenges.
  • Conduct initial candidate screenings through resume reviews, phone and video interviews, and automated assessments to assess candidate viability and build high-potential candidate pools.
  • Execute hub recruitment activities in alignment with Sanofi's global Early Careers recruitment strategy, processes, and best practices.
  • Ensure a positive candidate experience throughout recruitment; manage interview scheduling, assessment logistics, and onboarding activities; communicate proactively with candidates, hiring managers, and stakeholders across time zones as their main point of contact.
  • Proactively source early-career candidates in line with the Early Careers Sourcing strategy and provide recruiting advice to hiring managers to influence talent decisions.
  • Use Applicant Tracking Systems and other HR technologies to optimize recruitment processes, track metrics, generate reports, and ensure data accuracy and integrity.
  • Maintain knowledge of recruitment best practices and industry trends, identify operational opportunities to improve recruitment outcomes, and contribute to continuous process improvement.
  • Monitor industry trends, best practices, and emerging technologies to inform and adapt hub recruitment activities from an early-career perspective.
  • Build campus engagement and relationships with selected colleges and institutes across hub countries, maintaining ongoing connections to strengthen Sanofi's employer brand and recall.
  • Develop an external network among campus placement administrators and academicians.
  • Manage other projects across the end-to-end talent services line as needed.
  • Partner with the global Talent Acquisition Center of Excellence and Local Activation teams to align early-career recruitment with global strategy, best practices, and local market needs.
Desired Qualifications
  • Experience supporting recruitment in Global Business Services organizations.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...